Hutchmed (China) vs its peers
The 10 largest Pharmaceuticals companies by market value
Hutchmed (China) sits among the 10 biggest Pharmaceuticals companies on OQRO. Its revenue of $549M in fiscal 2025 ranks 10th of 10. It runs at an operating loss of 7% of revenue, against a group median margin of 19%. Revenue fell 13% on the year before, against a median of +3.3%.
Side by side
| Company | Market value | Revenue | Growth y/y | 5-yr growth / yr | Gross margin | Operating margin | Net margin | Free cash flow margin | R&D / revenue | Price / earnings | Price / sales | FCF yield | Stock, 12 months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli LillyLLY · FY2025 | $1.27T | $65.2B | +44.7% | +21.6% | 83.0% | — | 31.7% | — | — | 61.4x | 19.4x | — | +29.1% |
| Johnson & JohnsonJNJ · FY2025 | $651B | $94.2B | +6.0% | +2.7% | 67.9% | — | 28.5% | 20.9% | — | 24.3x | 6.9x | 3.0% |
Each company’s latest fiscal year (FY), so the years can end a few months apart. Price ratios divide today’s market value by that year’s figure; price / earnings is left out on a loss. “—” means the company did not tag that line in its annual report.
Operating margin
- RPRX66%
- ABBV25%
- TEVA12%
- HCM−7%
Revenue growth, latest year
- LLY+44.7%
- ABBV+8.6%
- JNJ+6.0%
- RPRX+5.1%
- TEVA
Compare Hutchmed (China) head to head
Where Hutchmed (China)’s revenue comes from and where it goes: Hutchmed (China) revenue breakdown. Twenty years of results: Hutchmed (China) financial history.
Common questions
Who are Hutchmed (China)'s competitors?
The largest companies in its industry (Pharmaceuticals) by market value: Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Teva Pharmaceutical Industries (TEVA), Royalty Pharma (RPRX) and Zoetis (ZTS). They share Hutchmed (China)'s industry listing; not every one competes with it on every product.
Which Pharmaceuticals company in this group is the most profitable?
Royalty Pharma, with 66% of revenue left as operating profit in fiscal 2025. Hutchmed (China): −7%.
Where these figures come from
The group is the companies OQRO lists in the same industry as Hutchmed (China) (Pharmaceuticals), the largest 9 by market value, plus Hutchmed (China). Companies whose latest annual report is more than a year and a half old, or that report in a currency other than the dollar, are left out.
Revenue, operating income, net income, gross profit, research and development and free cash flow (cash from operations minus capital expenditure) are each company’s own full-year lines from its latest 10-K, as tagged in XBRL (SEC companyfacts). Market value is the last close times the shares outstanding on the latest filing. Price / earnings is market value over net income; price / sales is market value over revenue; free cash flow yield is free cash flow over market value. Five-year growth is the yearly rate that takes revenue from five fiscal years before to the latest. This page describes the past and is not investment advice. No language model wrote it.








